A new study by Novartis has shown that patients with advanced pancreatic neuroendocrine tumours (NET), who received Afinitor in combination with Sandostatin LAR, remained progression-free for 16.7 months.
Novartis successfully demonstrated that treatment with Afinitor (everolimus) tablets, in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy, may have the potential to control tumour growth in patients with advanced pancreatic NET.
The Phase II study called RADIANT-1 included 160 patients, with pancreatic NET resistant to treatment with cytotoxic chemotherapy.
Patients who received Afinitor in combination with Sandostatin LAR remained progression-free for a median of 16.7 months, nearly four additional months since the first analysis was reported.
In addition, 84% of patients receiving combination therapy experienced a decrease in tumour size, patients who took Afinitor monotherapy remained progression-free for 9.7 months and nearly 60% of patients experienced a decrease in tumour size.
Novartis Oncology development executive vice-president and global head Alessandro Riva said that the biomarkers being studied in this trial would provide valuable insights into which patients are most likely to benefit from Afinitor, thus helping the company provide the right drug for the right patients.